2025-04-25 - Analysis Report
## Johnson & Johnson (JNJ) Stock Review

**0) Introduction:**  This report analyzes Johnson & Johnson (JNJ), a global healthcare company, based on provided financial data. Key metrics include cumulative return,  moving averages, RSI/PPO indicators, earnings, and financial statements.

**1) Cumulative Return and Comparison to S&P 500 (VOO):**

Johnson & Johnson's cumulative return is significantly lower than the S&P 500's.

* **JNJ Cumulative Return:** 37.66%
* **VOO (S&P 500) Cumulative Return:** 82.57%
* **Return Difference:** -44.9%
* **Relative Divergence:** 32.8% (This means JNJ's underperformance relative to the S&P 500 is in the 32.8th percentile of its historical range, indicating a considerable underperformance but not an extreme outlier.)


**Alpha and Beta Analysis:**

The provided data shows JNJ's alpha and beta fluctuating over the years, indicating periods of both outperformance and underperformance compared to the market.  Note that a negative alpha suggests underperformance relative to the market benchmark after adjusting for beta (market risk).  The beta values generally hover around 0.1 to 0.7, suggesting moderate sensitivity to market movements. Market capitalization remains consistently large.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 33.0% | 55.5% | 1.0% | 0.1 | 274.9 |
| 2016-2018  | 15.0% | 10.7% | -6.0% | -0.0 | 260.8 |
| 2017-2019  | 25.0% | 10.7% | -8.0% | 0.7 | 303.1 |
| 2018-2020  | 20.0% | 59.4% | -10.0% | 0.5 | 335.9 |
| 2019-2021  | 35.0% | 59.5% | -25.0% | 0.4 | 374.3 |
| 2020-2022  | 8.0% | 61.3% | -1.0% | 0.3 | 396.7 |
| 2021-2023  | -17.0% | 61.3% | -38.0% | 0.4 | 362.6 |
| 2022-2024  | -31.0% | 61.3% | -51.0% | 0.3 | 345.2 |
| 2023-2025  | -1.0% | 69.7% | -22.0% | 0.1 | 372.8 |


**2) Recent Price Movement:**

JNJ's recent price action shows a slightly downward trend.

* **Closing Price:** $154.93
* **5-Day Moving Average:** $156.49
* **20-Day Moving Average:** $155.535
* **60-Day Moving Average:** $158.4752

The price is below all three moving averages, suggesting a bearish short-term trend.  The recent slight decline (-$0.29) does not indicate a significant drop.


**3) Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.4053 (Medium Risk)
* **RSI:** 41.12 (Below 50, suggesting bearish momentum)
* **PPO:** 0.2659 (Positive, but relatively low, indicating weak bullish momentum)
* **Relative Divergence Change (20-day):** -8.2% (Short-term downward trend)
* **Expected Return (Long-term, 2+ years):** -53.6% (This indicates a significant underperformance compared to the S&P 500 over the long term. This projection should be treated with caution, as it is based on provided inputs and may not be wholly accurate.)


**4) Recent Earnings Analysis:**

Earnings data shows some fluctuation in EPS and revenue. While revenue remains relatively stable, EPS shows variability across quarters.  Note the duplicate entry for 2025-04-23. Data cleaning is necessary to ensure accuracy of further analysis.


| 날짜       | EPS  | 매출          |
|------------|------|---------------|
| 2025-04-23 | 4.57 | 21.89 B$      |
| 2024-10-23 | 1.12 | 22.47 B$      |
| 2024-07-25 | 1.95 | 22.45 B$      |
| 2024-05-01 | 1.35 | 21.38 B$      |
| 2025-04-23 | 1.35 | 21.38 B$      |


**5) Financial Information:**

Revenue remains relatively stable with slight fluctuations. Profit margins are consistently high but show a slight downward trend. Equity shows some fluctuations but remains substantial. ROE is volatile, suggesting inconsistent profitability.  Further analysis is needed to determine underlying causes.

**Revenue and Profitability:**

| Quarter     | Revenue    | Profit Margin |
|-------------|------------|---------------|
| 2025-03-31  | $21.89B    | 66.40%        |
| 2024-12-31  | $22.52B    | 68.35%        |
| 2024-09-30  | $22.47B    | 69.01%        |
| 2024-06-30  | $22.45B    | 69.40%        |
| 2024-03-31  | $21.38B    | 69.55%        |

**Capital and Profitability:**

| Quarter     | Equity     | ROE      |
|-------------|------------|----------|
| 2025-03-31  | $78.11B    | 14.08%   |
| 2024-12-31  | $71.49B    | 4.80%    |
| 2024-09-30  | $70.16B    | 3.84%    |
| 2024-06-30  | $71.54B    | 6.55%    |
| 2024-03-31  | $70.02B    | 4.65%    |


**6) Overall Analysis:**

JNJ's performance has lagged behind the S&P 500 significantly, particularly in recent years.  While the company maintains high profit margins and substantial revenue, the volatility in EPS and ROE raises concerns. Technical indicators suggest bearish momentum in the short term.  The projected long-term underperformance relative to the S&P 500 (-53.6%) is a major red flag.  Further investigation into the causes of fluctuating EPS and ROE is critical, along with a reassessment of the long-term projection, before making any investment decisions.  The duplicated data entry needs clarification and correction.  Additional data points would allow for a more robust analysis.
